Drug profile · INN
midodrine hydrochloride
ORVATEN
midodrine hydrochloride (ORVATEN) is a adrenergic receptor alpha-1 agonist. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Drug details — midodrine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
midodrine hydrochloride (ORVATEN) is a adrenergic receptor alpha-1 agonist. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha-1 agonist
Primary target: Adrenergic receptor alpha-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is midodrine hydrochloride?
midodrine hydrochloride (ORVATEN) is a adrenergic receptor alpha-1 agonist. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for midodrine hydrochloride?
ORVATEN is a marketed brand name for midodrine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of midodrine hydrochloride?
midodrine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.